Lundbeck closes RNA deal worth USD 109m with US biotech firm

Danish pharmaceutical firm Lundbeck enters a strategic collaboration with US biotech group Rgenta in order to find small molecules targeting RNA and develop new treatments for neurological diseases. To start with, the Danish company pays DKK 63m, and in time, it might end up paying DKK 628m in milestone payments.

Lundbeck Vice President Klaus Bæk Simonsen | Photo: Lundbeck / PR

New treatments for rare brain diseases in a potentially very lucrative market.

This could be the outcome of a new strategic research collaboration between Danish pharmaceutical company Lundbeck and US biotech firm Rgenta.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs